Bionor Pharma pulls in Nkr104m for advanced HIV drug trials
Bionor Pharma, the Norwegian biotech firm focused on developing a cure for HIV, will raise Nkr104m ($12.6m) after it simultaneously priced its private placement and announced a fully underwritten rights issue on Thursday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: